Trials / Completed
CompletedNCT05666128
Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 112 (actual)
- Sponsor
- Hyundai Pharm · Industry
- Sex
- All
- Age
- 19 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HD-6277 | HD-6277 100mg |
| DRUG | HD-6277 | HD-6277 50mg |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2022-06-17
- Primary completion
- 2023-06-28
- Completion
- 2023-07-28
- First posted
- 2022-12-27
- Last updated
- 2024-10-18
Locations
1 site across 1 country: South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05666128. Inclusion in this directory is not an endorsement.